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Summary
Current understanding of microRNA (miRNA) biology is limited, and antisense oligonucleotide (ASO) inhibition of miRNAs is
a powerful technique for their functionalization. To uncover the role of the liver-specific miR-122 in the adult liver, we in-
hibited it in mice with a 20-O-methoxyethyl phosphorothioate ASO. miR-122 inhibition in normal mice resulted in reduced
plasma cholesterol levels, increased hepatic fatty-acid oxidation, and a decrease in hepatic fatty-acid and cholesterol
synthesis rates. Activation of the central metabolic sensor AMPK was also increased. miR-122 inhibition in a diet-induced
obesity mouse model resulted in decreased plasma cholesterol levels and a significant improvement in liver steatosis,
accompanied by reductions in several lipogenic genes. These results implicate miR-122 as a key regulator of cholesterol
and fatty-acid metabolism in the adult liver and suggest that miR-122 may be an attractive therapeutic target for metabolic
disease.Introduction
MicroRNAs (miRNAs) are a class of endogenously expressed
small regulatory noncoding RNAs that are thought to negatively
regulate target mRNAs by binding with imperfect complemen-
tarity in their 30UTR (Ambros, 2004; Bartel, 2004; Du and
Zamore, 2005; He and Hannon, 2004). Originally identified in
C. elegans as important for the timing of larval development
(Lee et al., 1993), miRNAs have since been implicated in a variety
of processes in invertebrates, including cell proliferation, apo-
ptosis, and fat metabolism (Brennecke et al., 2003; Xu et al.,
2003). In mammals, only a few miRNAs have been assigned
any function, although they are predicted to regulate a large per-
centage of genes, with estimates based on bioinformatic target
prediction ranging as high as 30% (Lewis et al., 2005). Based on
the early studies in invertebrates, miRNAs are expected to have
similar roles in developmental regulation and cell differentiation
in mammals, and roles for miRNAs in cardiogenesis (Zhao et al.,
2005) and lymphocyte development (Chen et al., 2004) have
been demonstrated. Several studies have also found a strong
connection between miRNA and human cancer, including a re-
port thatmiRNA genes are often found in genomic regions linked
to cancer (Calin et al., 2004; McManus, 2003) and a study corre-
lating miRNA expression profiles with developmental lineage
and differentiation state of tumors (Lu et al., 2005). A potential
role for miRNAs in metabolic pathways has been suggested by
studies implicating miRNAs in regulation of adipocyte differenti-
ation (Esau et al., 2004) and glucose-stimulated insulin secretion
from pancreatic islet cells (Poy et al., 2004).
miR-122 is expressed in the developing liver (Chang et al.,
2004) and at high levels in the adult liver, where it makes up
70% of all miRNA (Chang et al., 2004; Lagos-Quintana et al.,
2002). It is one of many tissue-specific microRNAs thought to
be important for establishing patterns of gene expression thatCELL METABOLISM 3, 87–98, FEBRUARY 2006 ª2006 ELSEVIER INC.may be responsible for maintaining the differentiated state of a
tissue (Lagos-Quintana et al., 2002; Lim et al., 2005). miR-122
was also reported to enhance replication of HCV through a novel
mechanism that is not yet understood,making it a potential ther-
apeutic target for HCV infection (Jopling et al., 2005). Here we
report that inhibition of miR-122 in both normal and high-fat-
fed mice with a 20-O-methoxyethyl (20-MOE) phosphorothioate-
modified antisense oligonucleotide (ASO) for over 5 weeks was
well tolerated and was associated with a significant reduction in
hepatic steatosis and plasma cholesterol levels. These effects
were accompanied by a reduction in hepatic sterol and fatty-
acid synthesis rates and stimulation of hepatic fatty-acid oxida-
tion. The results suggest that miR-122 may be a therapeutic tar-
get for metabolic and cardiovascular diseases.
Results
Modulation of miR-122 activity in vitro
with miRNA antisense
In order to monitor ASO inhibition of miR-122, we first confirmed
regulation of several computationally predicted miR-122 target
genes using a 20-O-methoxyethyl-phosphorothioate-modified
ASO targeting miR-122 in primary mouse hepatocytes in vitro.
We have observed improved anti-miRNA activity using 20-
MOE ASO compared to the widely used 20-O-methyl (20-OMe)
modified ASO (see Figure S1 in the Supplemental Data available
with this article online). It is now recognized that miRNAs can
cause mRNA degradation of their target genes in addition to
translational regulation (Bagga et al., 2005; Lim et al., 2005).
Therefore, we monitored mRNA levels of miR-122 target genes
predicted by the TargetScan algorithm (Lewis et al., 2003, 2005)
using real-time TaqMan RT-PCR following transfection of ASO
into primary hepatocytes. Five out of six predicted targetmRNAs
examined were upregulated 1.5- to 3.5-fold after miR-122 ASODOI 10.1016/j.cmet.2006.01.005 87
A R T I C L EFigure 1. Identification of miR-122 target genes in vitro
A)TaqManRT-PCRmeasuringmRNAofpredictedmiR-122 targetgenesafter transfectionofprimarymousehepatocyteswith20-MOEASOtargetingmiR-122oracontrolASO.
B) TaqMan RT-PCR measuring mRNA of predicted miR-122 target genes after transfection of AML12 with miR-122 duplex RNA or miR-122 duplex RNA with four mis-
matches in the 50 seed region or the 30 half of the miRNA. Error bars represent standard deviation of triplicate samples.treatment, while none were affected by treatment with an unre-
lated control ASO (Figure 1A). Only the predicted target MINK1
was unaffected after miR-122 ASO treatment. To increase our
confidence that these target mRNAs were directly regulated88by miR-122, a reciprocal experiment was performed in which
amiR-122 RNA duplex was transfected into the mouse liver car-
cinoma AML12 cell line and target mRNA levels weremonitored.
Although miR-122 is highly expressed in primary hepatocytes, itCELL METABOLISM : FEBRUARY 2006
miR-122 regulation of lipid metabolismFigure 2. Inhibition of miR-122 in normal mice
Normal mice were treated i.p. with the indicated dose of miR-122 ASO or control ASO twice weekly for 4 weeks. n = 5.
A) Plasma transaminase levels measured at 4 weeks. Error bars = SEM.
B) Representative hematoxylin-and-eosin-stained liver sections from saline- or ASO-treated (75 mg/kg dose) mice, photographed at 403 magnification.
C) TaqMan RT-PCR measuring levels of miR-122 target genes in liver RNA. Error bars = SD.
D) Northern blotting for miR-122 in liver RNA.is dramatically reduced in most transformed liver cell lines ex-
amined, including AML12 cells (Chang et al., 2004). Transfection
of miR-122 into AML12 cells led to a decrease in mRNA level for
the same five targets that were upregulated by ASO treatment of
primary hepatocytes, while MINK1 was again unaffected (Fig-
ure 1B). The interaction of miRNAs with their targets is thought
to be primarily mediated through base pairing of the 50 ‘‘seed’’
portion of the microRNA at positions 2–8 (Lewis et al., 2003,
2005). To demonstrate that regulation of these genes depended
on the 50 seed region of the transfected miRNA, miR-122 with
four mismatches in either the 50 seed sequence or the 30 portion
of the miRNA were also transfected. In agreement with the
model for miRNA-target interactions, we found that mutation
of the 50 seed sequence ablated regulation of the target mRNA
while mutations in the 30 half of the miRNA had no effect (Fig-
ure 1B). Therefore, these five target mRNAs were regulated by
miR-122 in primary hepatocytes in vitro and may be used to
monitor antisense inhibition of miR-122 in vivo.CELL METABOLISM : FEBRUARY 2006Inhibition of miR-122 in normal mice
We have previously demonstrated that 20-MOE-modified ASOs
are very effective at inhibiting gene expression in liver without
further modification or formulation (Yu et al., 2005). Therefore,
normal mice were treated intraperitoneally with doses of miR-
122 ASO ranging from 12.5 to 75 mg/kg or with 75mg/kg of
a control ASO twice weekly for 4 weeks. The mice appeared
healthy and normal at the end of treatment, with no loss of body
weight or reduced food intake. Plasma transaminase levels were
in the normal range (AST% 45, ALT% 35) for all doses with the
exception of the 75mg/kg dose of miR-122 ASO, which showed
a very mild increase in ALT and AST levels (Figure 2A). Histolog-
ical analysis of liver sections revealed no gross changes in mor-
phology (Figure 2B). To demonstrate the efficacy of the miRNA
inhibition, the levels of the five miR-122 target mRNAs identified
in cell culture were evaluated in liver by TaqMan RT-PCR (Fig-
ure 2C). Four of the five target mRNAs were increased in the
miR-122 antisense-treatedmice,while no targetmRNAchanges89
A R T I C L EFigure 3. Plasma markers in normal mice after inhibition of miR-122
Plasma cholesterol, triglycerides, and glucose measured in normal mice that had been treated i.p. with the indicated dose of miR-122 or control ASO twice weekly for 4
weeks. n = 5. Error bars = SEM. *p < 0.05.were observed in mice treated with the control ASO, demon-
strating specific inhibition of miR-122 activity in liver. In addition,
three of the four target mRNAs showed a dose-dependent in-
crease in vivo by miR-122 ASO. P4HA1 mRNA appeared most
sensitive to miR-122 inhibition, as it displayed maximal upregu-
lation at the lowest ASO dose tested.
Northern blotting for miR-122 in liver RNA from these mice re-
vealed a 3-fold reduction in miR-122 level after treatment of
mice with the lowest dose of miR-122 ASO, 12.5 mg/kg, when
compared to saline-treated mice (Figure 2D). miR-122 levels
were reduced more than 10-fold after treatment with the highest
dose, 75 mg/kg. The control ASO treatment at the same dose
had no effect onmiR-122 levels in the liver. A control experiment
in which ASO was spiked into liver lysates before RNA prepara-
tion confirmed that the reduction ofmiR-122 signal on the North-
ern blot was not due to masking of the signal by ASO in the liver
RNA preparation (data not shown).
Plasma levels of total cholesterol, triglycerides, and glucose
were also monitored. After 4 weeks of ASO treatment, plasma
glucose levels were not significantly affected by miR-122 ASO
treatment compared to control ASO-treated mice (Figure 3).
However, we observed reductions in total cholesterol and tri-
glycerides in the plasma of miR-122 ASO-treated mice at all
doses tested, compared to saline or control ASO-treated mice
(Figure 3). Total cholesterol was reduced to a similar extent
(26%–28%) in mice treated with all doses tested of miR-122
ASO when compared to saline-treated mice.90Microarray analysis of liver gene expression
in miR-122 ASO-treated mice
To help elucidate themechanism of cholesterol lowering caused
by miR-122 inhibition in vivo, a cDNA microarray experiment
was performed. Liver gene expression was evaluated following
4 weeks of treatment with 50 mg/kg of miR-122 ASO twice
weekly and was compared with saline-treated animals (Tables
S1 and S2). Analysis of modulated genes by Gene Ontology cat-
egory revealed that many genes involved in regulation of lipid
and carbohydrate metabolism were affected in the ASO-treated
mice. Although several genes related to cholesterol metabolism
were reduced, only phosphomevalonate kinase mRNA downre-
gulation was statistically significant (Table 1). However, several
key genes known to regulate fatty-acid synthesis and oxidation
were also downregulated in themicroarray experiment and con-
firmed by RT-PCR, including FASN, ACC1, ACC2, SCD1, and
ACLY (Table 1).
Although the microarray experiment was designed primarily
to uncover the downstream effects of miR-122 inhibition after
chronic treatment rather than to identify direct miR-122 target
genes, we were able to identify 108 significantly upregulated
genes with a strict 7 or 8 nucleotide seed match in their 30UTR
(Table S3), which may be direct miR-122 target genes. Most of
these mRNAs were modestly increased by only 1.5- to 3-fold,
which was similar to the degree of modulation we observed
for the target genes identified in cultured hepatocytes after
miR-122 ASO transfection.CELL METABOLISM : FEBRUARY 2006
miR-122 regulation of lipid metabolismEx vivo analysis of lipid metabolism
The results of the cDNA microarray led us to examine the effect
of miR-122 inhibition on the rates of hepatic fatty-acid synthesis
and oxidation. Micewere treatedwith 25mg/kgmiR-122 or con-
trol ASO twice a week for 3 weeks. Hepatocytes were then iso-
lated from the treated mice, and the lipid metabolism rates were
measured in the cells after overnight culture. In accordance with
the observed reduction in FASN, ACC1 and ACC2 mRNA after
miR-122 inhibition, the fatty-acid synthesis rate was reduced
and the fatty-acid oxidation rate was increased almost 2-fold
in hepatocytes from miR-122 ASO-treated mice compared to
saline or control ASO-treated (Figure 4A). The rate of sterol syn-
thesis was also reduced (Figure 4B), whichmay contribute to the
lowered cholesterol levels measured in the plasma of the miR-
122 ASO-treatedmice. RT-PCR using RNA from the isolated he-
patocytes confirmed the reduction in SCD1 and ACC2mRNA in
the miR-122 ASO-treated cells (Figure 4C). A reduction in ACC1
was observed after miR-122 ASO-treatment but was also re-
duced in the control ASO-treated cells, suggesting that ACC1
reduction is not responsible for the observed effects on fatty-
acid synthesis or oxidation.
Increased fatty-acid oxidation could occur as a result of down-
regulation of ACC2 or an increase in activated AMPK (Hardie,
2003). Therefore, activated (phosphorylated) AMPK levels were
also examined by Western blotting of whole liver extracts of
mice treated with miR-122 ASO (50 mg/kg twice a week for 4
weeks) and compared to saline- or control ASO-treated mice.
Total AMPKa1 protein level was unchanged in the miR-122
ASO-treated mice, but the levels of phosphorylated AMPKa1
were indeed increased more than 2.5-fold compared to saline-
treated mice (Figure 4D).
Inhibition of miR-122 in diet-induced
obesity mouse model
To further examine the significance of the changes in lipid me-
tabolism observed in normal mice, C57Bl/6 mice that had
Table 1. Changes in gene expression aftermiR-122ASO treatment of normalmice
Microarray RT-PCR
Gene
Fold Change
from Saline p Value
Fold Change
from Saline p Value
Fatty-Acid Metabolism
ACACA/ACC1 0.7 0.136 0.7 0.050
ACACB/ACC2 0.4 0.016 0.4 0.002
ACLY 0.3 0.005 0.4 0.002
DGAT1 1.1 0.462 1.1 0.085
DGAT2 0.9 0.384 1.1 0.196
FASN 0.6 0.153 0.6 0.092
LIPC 0.7 0.023 0.8 0.117
PPARGC1A 1.0 0.782 1.1 0.619
PPARA 1.3 0.172 0.9 0.572
SCD1 0.5 0.004 0.2 0.001
SREBP1 0.4 0.004 0.5 0.002
SREBP2 1.0 0.780 0.9 0.016
Cholesterol Metabolism
CD36 1.4 0.247 0.7 0.014
HMGCR 0.8 0.129 0.8 0.154
LDLR 1.0 0.890 0.9 0.222
PMVK 0.4 0.007 ND
Liver RNA frommice treated twice weekly for 4 weeks with 50mg/kgmiR-122 ASO
or saline was used for a cDNA microarray experiment using GE CodeLink Mouse
Whole Genome chips or for TaqMan RT-PCR confirmation of array results. n = 5.
Shown are key genes related to lipid metabolism.CELL METABOLISM : FEBRUARY 2006been fed a high-fat diet for 19 weeks were treated twice a
week for 5 1/2 weeks with saline, miR-122 ASO, or control ASO
at 12.5 mg/kg, which was the lowest dose tested in the chow-
fedmouse study. Upregulation of miR-122 target mRNAs in liver
from themiR-122 ASO-treatedmice confirmed thatmiR-122 ac-
tivity had been effectively inhibited at this dose (Figure 5A).
Plasma cholesterol levels were reduced by 35%after twoweeks
of treatment, and were similarly reduced for the duration of the
study. (Figure 5B). Lipoprotein analysis performed using high-
performance liquid chromatography showed that the decrease
in total cholesterol reflected a reduction in both low-density lipo-
protein and high-density lipoprotein fractions (Figure 5C). Con-
sistent with the observed cholesterol reduction, levels of ApoB-
100 protein in the plasma of the miR-122 ASO-treated mice
were also markedly reduced compared to saline-treated mice,
as measured by Western blotting (Figure 5D). ApoB-48 protein
was not reduced, however, which is likely due to the fact that
themajority of ApoB-48 protein in plasma originates in the intes-
tine rather than the liver (Xie et al., 2003), and miR-122 is not ex-
pressed in the intestine (Shingara et al., 2005). Histological anal-
ysis of the liver showed substantial reduction of liver steatosis
after miR-122 inhibition (Figure 6A), which was also reflected in
the reduced levels of triglyceride accumulation in the livers of
these mice compared to control ASO-treated (Figure 6A). This
was accompanied by a trend toward reduction of plasma trans-
aminase levels in miR-122 ASO-treated mice, indicating an im-
provement in hepatic function (Figure 6B), although the p value
obtained from an analysis of variance was relatively high (p = 0.1
for both AST and ALT). As observed in normal mice, these
changes also correlated with a reduction in mRNA levels of
the same key lipogenic enzymes FASN, ACC2, and SCD1
(Figure 6C).
Discussion
Although many miRNAs are ubiquitously expressed, a subset
are tissue-specifically expressed during development and are
presumed to be important for tissue differentiation. A study ex-
amining expression of miRNAs through development in zebra-
fish found that miRNAs are expressed not early in development
but rather after tissue-fate specification, and this study con-
cluded that miRNAs are likely to be more important for later dif-
ferentiation and maintenance of tissue identity (Wienholds et al.,
2005). miR-122 is one such tissue-specificmiRNA. It is gradually
upregulated in the mouse liver during embryogenesis (Chang
et al., 2004) and is likely to regulate aspects of liver development
that will eventually be revealed in a germline knockout mouse.
The role of miR-122 in the adult liver, however, may be difficult
to determine in a knockout mouse, and antisense inhibition is
a convenient and effective technique for functionalization of
miRNAs in cell culture and in animals (Hutvagner et al., 2004;
Krutzfeldt et al., 2005; Meister et al., 2004). In this study, we
set out to examine the importance of miR-122 for normal liver
function in adult mice by inhibiting miR-122 in vivo with an anti-
sense oligonucleotide. The consequences of inhibiting the most
abundant miRNA in the liver were surprisingly mild, given the
broad role that miRNAs are expected to play in gene regulation.
However, we have uncovered an unexpected role for miR-122 in
regulation of hepatic lipid metabolism.
Evidence to date indicates that miRNAs negatively regulate
their target mRNAs posttranscriptionally by binding in the 30UTR.91
A R T I C L EFigure 4. Ex vivo analysis of lipid metabolism after miR-122 inhibition
Hepatocytes isolated from mice treated with miR-122 ASO or a control ASO (25 mg/kg) twice weekly for 3 weeks were used for subsequent in vitro measurement of fatty-
acid and sterol synthesis rates and fatty-acid oxidation rates. Shown are results from five mice per group, with each measurement done in triplicate. Error bars = SEM.
*p < 0.05.
A) Fatty-acid oxidation rate in isolated hepatocytes as measured by oxidation of [1-14C]oleate into 14CO2 and [
14C]ASPs; de novo fatty-acid synthesis rate as measured by
the amount of [14C]acetate incorporated into fatty acids.
B) Sterol synthesis rate in isolated hepatocytes as measured by amount of [14C]acetate incorporated into sterols inside cells or secreted into the culture medium.
C) TaqMan RT-PCR measuring mRNA levels in isolated hepatocytes of genes involved in lipid metabolism.
D)Western blotting for phospho-AMPKa1 catalytic subunit in liver extracts frommice treated withmiR-122 ASO or control ASO in vivo twice weekly (50mg/kg) for 4 weeks.
The pictured gel shows pooled samples for each group, but quantitation is from n = 5 samples per group.The mechanism of downregulation in animals is believed to in-
volve primarily translational repression. However, there is now
ample evidence to indicate that miRNA regulation can result in
mRNAdegradation (Bagga et al., 2005; Limet al., 2005), possibly
by recruiting the mRNA to cytoplasmic sites of mRNA storage
and degradation referred to as processing bodies (Liu et al.,
2005; Sen and Blau, 2005). We were able to confirm the regula-92tion of several predicted miR-122 target mRNAs by measuring
mRNA levels in cell culture and in mice after miR-122 ASO treat-
ment. We did not evaluate translational regulation of the pre-
dicted targets, so it is possible that theremaybeadditional trans-
lational regulation of other targets such as the predicted target
MINK1, which did not show any mRNA modulation in response
to miR-122 inhibition or addback.CELL METABOLISM : FEBRUARY 2006
miR-122 regulation of lipid metabolismFigure 5. Cholesterol lowering in diet-induced obesity mouse model after miR-122 inhibition
C57Bl/6 mice that had been fed a high-fat diet for 19 weeks were treated s.c. with 12.5 mg/kg miR-122 or control ASO twice weekly for 5 1/2 weeks. n = 5.
A) TaqMan RT-PCR measuring levels of miR-122 target genes in liver RNA after treatement. Error bars = SD.
B) Plasma cholesterol levels at various time points after start of treatment. Error bars = SEM. *p < 0.05.
C) High-performance liquid chromatography analysis of lipoprotein profiles in treated mice.
D) Plasma ApoB-100 and ApoB-48 levels measured byWestern blotting and normalized to nonspecific band. Graph represents the average of four samples per groupwith
the standard deviation indicated.Although miR-122 is the most abundant miRNA in hepato-
cytes, the magnitude of the target mRNA modulation, both in
cell culture and in mice, was 1.5- to 3.5-fold. The variation we
observed in the dose response to miR-122 ASO treatment in
normal mice suggests that each target mRNA may have differ-
ential sensitivities to miRNA levels. For example, the target
P4HA1 appeared to be maximally affected even at the lowest
ASO dose tested, while regulation of GYS1 was more dose re-
sponsive. We also performed a cDNA microarray experiment
that was designed not to identify direct miR-122 target genes
but rather to characterize the effect of chronic miR-122 inhibi-
tion. Nevertheless, we were able to identify 108 upregulated
genes with strict 7 or 8 nucleotide seed matches in their
30UTR, implicating them as direct miR-122 target genes. Few
of these genes were computationally predicted miR-122 tar-
gets, suggesting that the current algorithms in use are still insuf-
ficient to capture the breadth ofmiRNA gene regulation. Surpris-
ingly, given the effects we observed on lipid metabolism after
miR-122 inhibition, only a few genes known to be involved in
lipid metabolism were on this list of potential miR-122 target
genes. These putative miR-122 target genes identified by the
microarray experiment were also found to be increased byCELL METABOLISM : FEBRUARY 20061.5- to 3-fold. The relationship of miRNA abundance to themag-
nitude of target modulation or the mechanism (translational
repression or mRNA degradation) is not at all understood, but
it will be interesting to evaluate whether changes in target mRNA
levels will be so easily detectable after inhibition of less abun-
dant miRNAs. Are translational repression and mRNA degrada-
tion mutually exclusive outcomes of miRNA regulation, or are
they on a continuum, either temporally or relating to the level
of miRNA repression?
Given the abundance of miR-122 in the liver, it was expected
to play an important role in maintenance of liver differentiation.
Surprisingly, themost apparent consequence of miR-122 inhibi-
tion in normal mice over 4 weeks was a lowering of plasma cho-
lesterol. The cholesterol lowering was observed in chow-fed
mice at a relatively low dose of 25mg/kg/weekmiR-122 ASO af-
ter 4 weeks, and it was not further improved by higher dosing
even though miR-122 levels as measured by Northern blot
were more reduced after treatment with a higher dose of ASO.
In the high-fat-fed mice, the same 25 mg/kg/week dose of
miR-122ASOcaused plasma cholesterol lowering of about 35%
compared to saline-treated animals after only 2 weeks of treat-
ment, and treatment for another 3 weeks did not further reduce93
A R T I C L EFigure 6. Improvement in liver steatosis in high-fat-fed mice after miR-122 inhibition
C57Bl/6mice that had been fed a high-fat diet for 19weeks were treated s.c. with 12.5mg/kgmiR-122 or control ASO twiceweekly for 5 1/2 weeks. n = 5. Error bars = SEM.
A) Representative hematoxylin-and-eosin-stained liver sections photographed at 203magnification and hepatic triglyceride content after 5 1/2 weeks of ASO treatment.
B) Plasma transaminase levels measured after 5 1/2 weeks of ASO treatment.
C) TaqMan RT-PCR evaluating liver mRNA levels of genes involved in lipid metabolism.cholesterol levels. These data suggest that the cholesterol low-
ering caused by miR-122 inhibition is not dose-responsively re-
lated to the level of inhibition of miR-122. Rather, inhibiting
a threshold level of miR-122 results in a change in the steady-
state level of plasma cholesterol that does not respond to further
inhibition of miR-122. It is likely that this threshold corresponds
to the maximal relief from miR-122 regulation of miR-122 tar-
get genes responsible for the cholesterol-lowering phenotype.
The microarray experiment identified several modulated genes
known to be important in cholesterol metabolism, the most
prominent being phosphomevalonate kinase (PMVK), which
was downregulated more than 2-fold in the livers of miR-122
ASO-treated mice. However, this gene is not likely to be a direct
miR-122 target as it does not contain a miR-122 seed sequence
and is downregulated after miR-122 inhibition. Further work will
be required to pinpoint which target genes are responsible for
cholesterol lowering.
The decreases in plasma cholesterol observed after miR-122
inhibition reflected reductions in both the high-density and low-
density lipoprotein fractions. In mice, unlike in humans, HDL
makes up the majority of plasma cholesterol, and one would
predict that any drug that significantly lowers total plasma cho-94lesterol levels in mice would have effects on HDL levels. Further
experiments in primates or hamsters will be required to evaluate
the relative effects of miR-122 inhibition on HDL and LDL in spe-
cies that have lipoprotein profilesmore similar to humans. These
will be helpful studies in evaluating the prospects for therapeu-
tically inhibiting miR-122 to lower cholesterol in humans.
The microarray experiment uncovered significant decreases
in the mRNA levels of many key genes that regulate lipid metab-
olism, including FASN, ACC2, SCD1, and ACLY. As inhibition of
miR-122 is expected to result in upregulation of its direct tar-
gets, the exact connection between inhibition of miR-122 and
downregulation of these genes is not clear. One possibility is
that a transcriptional inhibitor of these genes is negatively regu-
lated by miR-122 and therefore upregulated following miR-122
inhibition, potentially at the level of translation that would not
have been identified in the microarray experiment. Also, the ef-
fects of depleting a substantial amount of miRNAs in a cell on
the activity of other miRNAs have not been explored, but there
could be consequences for RISC formation and activity of other
miRNAs after miR-122 inhibition. The possibility that miR-122
could be directly downregulating these genes through interac-
tion with their 30UTRs is not likely, as they do not contain seedCELL METABOLISM : FEBRUARY 2006
miR-122 regulation of lipid metabolismsequences for miR-122, unless the miRNA is acting through
a novel mechanism.
From the decreases we observed in the key lipogenic genes
after miR-122 inhibition, we would predict profound negative ef-
fects on lipogenesis in these animals. Reduction in ACC genes,
particularly ACC2, is expected to cause a decrease in malonyl
CoA levels and a subsequent increase in fatty-acid oxidation
(Saha and Ruderman, 2003). The result is a switch from an
energy-storage to an energy-generating state in the cell. Eval-
uation of fatty-acid metabolism rates in hepatocytes from
miR-122 ASO-treated mice confirmed this. After miR-122 ASO
treatment, the hepatic fatty-acid oxidation rate was increased
2-fold compared to saline treatment, and fatty-acid synthesis
was down almost 2-fold. The sterol synthesis rate was also
down significantly after miR-122 ASO treatment, which is likely
at least partially responsible for the plasma cholesterol lowering
observed in these mice. These changes in lipid metabolism
measured in hepatocytes were also correlated with mRNA re-
ductions in the key genes ACC2 and SCD1 that are important
for regulation of fatty-acid oxidation and synthesis.
The central metabolic sensor AMPK is a key regulatory en-
zyme that acts to promote ATP-generating pathways such as
fatty-acid oxidation and inhibits energy-storage pathways
such as fatty-acid synthesis (Kahn et al., 2005). Because the
phenotype that we observed following miR-122 inhibition in
micewas consistentwith increasedAMPKactivity, weexamined
the effect ofmiR-122 inhibition on this enzyme. Indeed,we found
a 2.5-fold increase in the levels of activated AMPK as measured
by phosphorylation of the a1 catalytic subunit. However, it is not
clear whether AMPK activation is a secondary consequence of
miR-122 regulation of other pathways involved in control of lipid
metabolism, as a reduction in SCD1 is sufficient to promote
AMPK activation (Dobrzyn et al., 2004). Alternatively, inhibition
of miR-122 may first promote AMPK activation through a mech-
anism still to be determined, which then promotes the switch in
energy usage by inhibiting the ACC2 and FASN.
The modulation of lipid metabolism had profound phenotypic
effects in the diet-induced obesity mouse model, in which in-
creased fatty-acid oxidation after miR-122 inhibition led to a sig-
nificant improvement in liver steatosis in addition to cholesterol
lowering. These high-fat-fed mice represent a state of pro-
longed caloric excess, which results in obesity, hyperlipidemia,
and hepatic steatosis. An increase in fatty liver has been impli-
cated in the pathogenesis of several metabolic disorders, in-
cluding nonalcoholic steatohepatitis (NASH) and insulin resis-
tance (Sanyal, 2005). Our data suggest that miR-122 normally
plays a significant role in promoting lipid synthesis and inhibiting
fatty-acid oxidation in the adult liver and may be a therapeutic
target for metabolic and cardiovascular diseases.
During the preparation of this manuscript, Krutzfeldt et al.
(2005) reported the inhibition of miR-122 in mice using a choles-
terol-conjugated 20-OMe-modified ASO. Using an acute dosing
schedule over 4 days, they demonstrated reduction of miR-122
in the liver and cholesterol lowering in plasma. Although the ASO
design and dosing schedules were very different in our respec-
tive studies, our results showing cholesterol lowering are in
good agreement. Comparing the two microarray experiments,
Krutzfeldt et al. identifiedmore changes in genes relating to cho-
lesterol metabolism, which may reflect the earlier time point of
their experiment, before compensatory changes in gene expres-
sion are seen in the liver in response to lower cholesterol levels.CELL METABOLISM : FEBRUARY 2006Despite the differences between the experiments, there were
many overlapping gene changes (Table S4). In our studies, how-
ever, we have extended the analysis of the consequences of
miR-122 inhibition to find additional roles for miR-122 in general
lipid metabolism.
Inhibition of miR-122 as reported by Krutzfeldt et al. (2005)
using the cholesterol-conjugated 20-OMe ASO involved degra-
dation of the microRNA, which we also observed using an un-
conjugated 20-MOE ASO. Although the 20-MOE ASO was ad-
ministered at lower doses with a less acute dosing schedule in
these studies, it was also effective at miR-122 degradation, tar-
get-gene upregulation, and cholesterol lowering in normal mice.
This indicates that a conjugation strategy for miRNA-targeting
ASOs is not required for effective miRNA inhibition. However,
the onset of action of the 20MOE ASO does appear to be slower,
as a similar acute dosing schedule did not produce cholesterol
lowering and produced onlyw50% reduction of miR-122 (data
not shown). Krutzfeldt et al. also reported on the degradation
of miR-122 in vivo with the conjugated but not the unconjugated
20-OMe ASO. We have observed in in vitro experiments that the
20-MOE-modified ASOs aremore effective than 20-OMeASOs at
inhibiting miRNA activity as measured by a luciferase sensor re-
porter or a target mRNA in HeLa cells and primary hepatocytes
(Figure S1 and data not shown). This may partially explain the
ineffectiveness of the unconjugated 20-OMe ASO at causing
miRNA degradation. Krutzfeldt et al. did not report on the ability
of the unconjugated 20-OMe ASO to modulate miR-122 target
genes or cause cholesterol lowering, so it is still possible that
the unconjugated 20-OMe ASO can inhibit miRNA activity by se-
questering the miRNA without causing degradation.
The results presented here demonstrate that miRNA function
can be modulated in rodents using antisense oligonucleotides.
Surprisingly, reducing the levels of the most abundant miRNA
in the liver by 90% did not produce any untoward effects over
a period of 4 weeks. To the contrary, inhibition of miR-122 pro-
duced a beneficial effect on plasma cholesterol and hepatic
fatty-acid metabolism, improving liver steatosis in a high-fat-
fed mouse model. Although much more work is needed to un-
derstand all the roles of miR-122 in liver biology and the general
role of miRNA in regulation of gene expression, these results
portend the therapeutic potential of miRNA modulation.
Experimental procedures
Oligonucleotide synthesis and sequence
Oligonucleotides were prepared using conventional phosphoramidite chem-
istry and DNA synthesis equipment (ABI). The 20-O-methoxyethyl phosphor-
amidites and succinate-linked solid support were prepared as described
previously (Martin, 1995). Synthesis of ASOs for animal treatments was as
described previously (Cheruvallath et al., 2003). The miR-122 ASO sequence
was 50-ACAAACACCATTGTCACACTCCA-30. Control ASOs used for cell
culture experiments were either a six-mismatch miR-122 ASO of sequence
50-ACATACTCCTTTCTCAGAGTCCA-30 or an unrelated control of sequence
50-CCTTCCCTGAAGGTTCCTCCTT-30. The unrelated control ASO was used
for all animal experiments.
Isolation and transfection of primarymouse hepatocytes and AML12
Primary hepatocytes were isolated from Balb/cmice as previously described
(Neufeld, 1997). Cells were seeded into 96-well plates in culturemedium (Wil-
liams’ Medium E supplemented with 10% fetal bovine serum, 10 nM HEPES,
and penicillin/streptomycin) and cultured overnight before transfection.
Transfection of oligonucleotide in Lipofectin (Invitrogen) was performed in
triplicate according to the manufacturer’s instructions. Cells were lysed
24 hr after transfection, and total RNA was harvested using QIAGEN RNeasy95
A R T I C L E96 columns on a Bio Robot 3000 (QIAGEN). Transfection of AML-12 cells with
miR-122 duplexed RNA was done using Lipofectamine 2000 (Invitrogen).
miR-122 duplex RNA was purchased from Dharmacon. miR-122 duplex:
50-UGGAGUGUGACAAUGGUGUUUGU-30 (miR), 50-AAACACCAUUGUCA
CACUCCAUA-30 (complement). 50mm miR-122: 50-UGCACAGAGACAA
UGGUGUUUGU-30 (miR), 50-AAACACCAUUGUCUCUGUGCAUA-30 (com-
plement). 30mm miR-122: 50-UGGAGUGUGACAUUGCAGUAUGU-30 (miR),
50-AUACUGCAAUGUCACACUCCAUA-30 (complement).
Animal care and treatments
All animal experiments were conducted according to the Institutional Amer-
ican Association for the Accreditation of Laboratory Animal Care Guidelines.
Male C57BL/6 mice were obtained from The Jackson Laboratory and were
housed 4–5 animals per cage with a 12 hr light/dark cycle. Oligonucleotides
were dissolved in saline and administered to mice based on body weight by
intraperitoneal or subcutaneous injection twice weekly. At study termination,
micewere sacrificed in themorning, and liver, kidney, spleen, and epididymal
fat pads were removed for further analysis. For diet-induced obesity (DIO)
studies, mice were fed a Western diet of 60% lard (Research Diets) for 19
weeks before treatment with oligonucleotide.
Histological analysis
Liver was fixed in 10%buffered formalin and embedded in paraffin wax. Four
millimeter sections were cut and mounted on glass slides. After dehydration,
the sections were stained with hematoxylin and eosin.
Metabolic measurements
Plasma concentrations of glucose, transaminases, triglycerides, total cho-
lesterol, HDL cholesterol, and LDL cholesterol were determined with an
Olympus AU400e automated clinical chemistry analyzer (Melville, NY). Liver
triglyceride levels and glycogen contents were analyzed as previously de-
scribed (Desai et al., 2001).
HPLC analysis of lipoproteins
Serum lipoprotein profiling was performed as described (Kieft et al., 1991)
with a Beckman SystemGold 126 HPLC system, 507e refrigerated autosam-
pler, 126 photodiode array detector (Beckman Instruments), and a Superose
6 HR 10/30 column (Pfizer). HDL, LDL, and VLDL fractions were measured
at a wavelength of 505 nm and validated with a cholesterol calibration kit
(Sigma). For each experiment, a three-point standard curve was performed
in triplicate to determine the absolute concentration of each lipoprotein
fraction.
RT-PCR analysis
Total RNA extracted from whole liver tissue or cultured cells with QIAGEN
RNeasy isolation kits was used for real-time quantitative RT-PCR analysis
with a Prism 7700 Sequence Detector (Applied Biosystems). mRNA levels
were normalized to total RNA for each sample as measured by Ribogreen.
All reagents were from Invitrogen. TaqMan primer/probe sequences used
for RT-PCR are available on request.
Northern blotting
RNA from livers of treated mice was homogenized in Trizol (Invitrogen) and
isolated according to the manufacturer’s instructions. Total RNA was sepa-
rated on a 14%acrylamide TBE 8M ureaminigel containing 20% formamide,
then electroblotted onto Hybond N+ nylon filter (Amersham). An end-labeled
(Promega) oligonucleotide probe for miR-122 (50-ACAAACACCATTGTCA
CACTCCA-30) was hybridized to the filter in Rapidhyb buffer (Amersham).
The blot was reprobed for U6 to control for equal loading. Quantitation was
done using a Storm 860 phosphorimager (Molecular Dynamics) and Image-
Quant software.
Western blotting
For detection of ApoB levels, plasma diluted 1:80 in lysis buffer (50 mM Tris
[pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% NP40, 1% Triton,
0.25% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail 1:100,
0.2 mM orthovanadate) was electrophoresed on 4%–12% Tris-glycine
gels, transferred to PVDF membrane (Invitrogen), and blotted for ApoB-
100/-48 with polyclonal antiserum kindly provided by Dr. Stephen G. Young
(University of California, Los Angeles). For AMPK and phosphor-AMPK de-96tection, homogenized liver lysates were electrophoresed on a 10% Tris-gly-
cine gel, transferred to PVDF membrane, and blotted for p-AMPK-1a (Cell
Signaling) or total AMPK-1a (Upstate Biotechnology). Protein bands were
visualized using the ECL Plus Western blot detection kit (Amersham Biosci-
ences) and quantitated using ImageQuant software (Molecular Dynamics).
Microarray
The microarray experiment design was a treatment-control comparison with
five mice per group. Liver RNA was isolated frommale C57Bl/6 mice injected
i.p. 23/week for 4 weeks with 50 mg/kg miR-122 ASO or saline. RNA from
homogenized liver extracts was initially purified by overnight centrifugation
after layering onto 5.7 M CsCl2. The pellet was then run through an RNeasy
column (Invitrogen) according to the manufacturer’s instructions. Microarray
analysis was performed by staff at the Biomedical Genomics Laboratory
(BIOGEM) at the University of California, San Diego (Dr. Gary Hardiman, Di-
rector) using the CodeLink Mouse Whole Genome Bioarray (Amersham-GE).
Preparation of the target RNA for hybridization was done as described in
Ramakrishnan et al. (2002). Ten micrograms of fragmented target aRNA
was used for hybridization to the microarrays. The microarrays were then
washed and processed using a direct detection method of the biotin-
containing transcripts by a streptavidin-Alexa 647 conjugate as described
previously (Ramakrishnan et al., 2002). Processed slides were scanned using
an Agilent Microarray Scanner using CodeLink Scanning Software (Motorola
Life Sciences) with the laser set to the red dye channel, a Red PMT setting of
70%, and a scan resolution of 5 mm. Images for each slide were quantitated
using CodeLink Expression Analysis Software V4.0 (Amersham-GE). Signal
intensities for each spot were calculated by summation of the pixel intensities
for each spot, then the local background (based on themedian pixel intensity
of the area surrounding each spot) was subtracted. Whole-array data nor-
malization was performed independently for each slide by dividing each
spot’s intensity (after background subtraction) by the median signal intensity
of all test probes. The resulting data set for each array provided intensities for
each probe that were background corrected and normalized to the median
intensity of all probes on the array. Pairwise statistical analysis comparing
the antisense-treated group with saline control group was performed using
Pipeline Pilot (Scitegic, San Diego, CA) and GeneSifter (VisX Labs, Seattle).
The median-normalized spot intensities resulting from the CodeLink Analysis
Software were log 2 transformed, the mean and standard deviation were cal-
culated, and a two-tailed Student’s t test was used to evaluate the signifi-
cance of changes. During evaluation of the results, data were filtered requir-
ing a p value < .05 and a fold change > 1.5 up or down. From this list,
associations to NCBI RefSeq sequences were determined from the relation-
ship of CodeLink probes to Entrez Gene entries, then 30UTR regions excised
based on GenBank sequence annotations. This provided 30UTR sequences
for 494 out of 721 probes that were upregulated > 1.5 fold with p value > 0.05.
Determination of sterol and fatty-acid synthesis
and fatty-acid oxidation rate
Hepatocytes were isolated as described from male C57Bl/6 mice treated
with saline, miR-122 ASO, or control ASO for 3 weeks (25 mg/kg body
weight, twice/week for five doses, hepatocyte isolation done 2 days after
the last dose). Cells from each animal were plated in triplicate for each assay.
For the measurement of sterol and fatty-acid synthesis, 106 cells were
seeded into each 60 mm plate in supplemented Williams’ E medium (10 nM
insulin and 10% FBS). After overnight culture, the cells were used for the de-
termination of sterol synthesis and fatty acid synthesis rate by measuring the
incorporation of [14C]acetate into sterols and fatty acids, respectively, as de-
scribed previously (Jiang et al., 2005). For the measurement of fatty acid ox-
idation rate, 106 cells were seeded into each 25 cm2 flask in supplemented
Williams’ Medium E. Fatty-acid oxidation rate was evaluated by measuring
the oxidation of [1-14C]oleate into 14CO2 and acid-soluble products as de-
scribed (Yu et al., 1997; Yu et al., 2005). Radioactivity levels measured
were normalized to total protein for each flask.
Supplemental data
Supplemental Data include one figure and four tables and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/3/2/87/
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